FDA Just Approved Eli Lilly's Weight-Loss Pill. Here's What It Means for LLY.

GLP-1 dominance just got priceless. Plus: SpaceX IPO incoming and Fastly's 219% Q1 surge. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  

April 3, 2026 FDA Clears Eli Lilly's Weight-Loss Pill – Here's Why GLP-1 Dominance Just Got Priceless Eli Lilly secured FDA approval for Foundayo, its once-daily oral GLP-1 weight-loss pill. Already the dominant player in injectables, the company now challenges Novo Nordisk's early oral entry in a rapidly expanding market. Read more. › Sponsored The #1 Stock to Buy BEFORE the SpaceX IPO Bloomberg is calling Elon Musk's upcoming SpaceX IPO "the biggest listing of ALL TIME." Most investors will be locked out until after it goes public. Dr. Mark Skousen has found a backdoor that lets everyday Americans grab a pre-IPO stake right now. Get the free SpaceX ticker. › Record-Breaking SpaceX IPO Is Coming. Is This Your Rocket Ride to Riches? SpaceX's IPO looks like a go. Targeting a roughly $1.75 trillion valuation – the largest in history – it also plans to reserve 30% of shares to retail investors. Buying into this Musk-led venture is bound to be a volatile ride. Read more. › Fastly's 219% Q1 Surge: Here's the Growth Math That Still Works in 2026 Fastly shares surged 219% in Q1, fueled by record revenue growth and strong AI tailwinds. With 110% net retention, rising enterprise customers, and 2026 guidance pointing to more records being set, this rally still has legs. Read more. › You are receiving this e-mail at reditudo@gmail.com, as part of your subscription to Money Morning. Manage Your Preferences by clicking here. No longer interested? Unsubscribe. © 2026 Money Morning. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before our subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication prior to following an initial recommendation. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Agora Media, 14 West Mt Vernon Place, Baltimore, MD 21201. Money Morning is a First Light Financial, LLC publication. To contact us call 866-616-2166 or visit us online. Website  |  Privacy Policy  |  Terms & Conditions